Cellular reprogramming to reverse aging and promote organ and tissue regeneration

Patent metadata

Field	Value
Publication number	US-12414982-B2
Application number	US-202418583147-A
Country	US
Kind code	B2
Filing date	Feb 21, 2024
Priority date	Sep 28, 2018
Publication date	Sep 16, 2025
Grant date	Sep 16, 2025

Abstract

Provided herein are engineered nucleic acids (e.g., expression vectors, including viral vectors, such as lentiviral vectors, adenoviral vectors, AAV vectors, herpes viral vectors, and retroviral vectors) that encode OCT4; KLF4; SOX2; or any combination thereof that are useful, for example, in inducing cellular reprogramming, tissue repair, tissue regeneration, organ regeneration, reversing aging, or any combination thereof. Also provided herein are recombinant viruses (e.g., lentiviruses, alphaviruses, vaccinia viruses, adenoviruses, herpes viruses, retroviruses, or AAVs) comprising the engineered nucleic acids (e.g., engineered nucleic acids), engineered cells, compositions comprising the engineered nucleic acids, the recombinant viruses, engineered cells, engineered proteins, chemical agents that are capable of activating expression of OCT4; KLF4; SOX2; or any combination thereof, an engineered protein selected from the group consisting of OCT4; KLF4; SOX2; or any combination thereof, an antibody capable of activating expression of OCT4; KLF4; SOX2; or any combination thereof, and methods of treating a (e.g., ocular disease), preventing a disease (e.g., ocular disease), regulating (e.g., inducing or inducing and then stopping) cellular reprogramming, regulating tissue repair, regulating tissue regeneration, or any combination thereof).

First claim

What is claimed is:

1. A method of increasing survival and/or regeneration of neuronal cells, the method comprising:
contacting the neuronal cells with one or more polynucleotides encoding OCT4, SOX2, and KLF4, but not c-Myc, operably linked to one or more promoters, or an expression vector comprising the one or more polynucleotides,
wherein the method maintains the neuronal cells as neuronal cells without loss of cellular identity.

2. The method of claim 1 , wherein the one or more promoters are inducible promoters.

3. The method of claim 2 , wherein the one or more inducible promoters comprise:
a mifepristone-responsive promoter, or
a coumermycin-responsive promoter.

4. The method of claim 2 , wherein the one or more inducible promoters comprise one or more tetracycline-responsive elements (TREs).

5. The method of claim 4 , wherein the method comprises introducing into the neuronal cells a polynucleotide encoding a reverse tetracycline-controlled transactivator (rtTA).

6. The method of claim 5 , wherein the expression vector comprises the polynucleotide encoding the rtTA.

7. The method of claim 2 , wherein the inducible promoter is a TRE3G promoter.

8. The method of claim 2 , wherein the method comprises administering an inducing agent for the one or more inducible promoters.

9. The method of claim 8 , wherein the inducing agent is a tetracycline-class antibiotic.

10. The method of claim 8 , wherein the inducing agent is tetracycline.

11. The method of claim 8 , wherein the inducing agent is doxycycline.

12. The method of claim 1 , wherein the method further comprises measuring expression of one or more of Esrrb, Nanog, Lin28, TRA-1-3/TRA-1-81/TRA-2-54, SSEA1, or SSEA4.

13. The method of claim 1 , wherein the method further comprises measuring DNA methylation-based age (DNAmAge) in the neuronal cells.

14. The method of claim 1 , wherein the method further comprises measuring expression of Nanog.

15. The method of claim 1 , wherein the expression vector is an adeno-associated virus (AAV) vector.

16. The method of claim 1 , wherein the expression vector is a lentiviral vector.

17. The method of claim 1 , wherein the expression vector comprises a polynucleotide sequence encoding a self-cleaving peptide.

18. The method of claim 1 , wherein:
i) OCT4 comprises an amino acid sequence having at least 90% identity to SEQ ID NO: 41;
ii) SOX2 comprises an amino acid sequence having at least 90% identity to SEQ ID NO: 43; and
iii) KLF4 comprises an amino acid sequence having at least 90% identity to SEQ ID NO: 45.

19. The method of claim 1 , wherein:
i) OCT4 comprises an amino acid sequence having at least 95% identity to SEQ ID NO: 41;
ii) SOX2 comprises an amino acid sequence having at least 95% identity to SEQ ID NO: 43; and
iii) KLF4 comprises an amino acid sequence having at least 95% identity to SEQ ID NO: 45.

20. The method of claim 1 , wherein:
i) OCT4 comprises the amino acid sequence of SEQ ID NO: 41;
ii) SOX2 comprises the amino acid sequence of SEQ ID NO: 43; and
iii) KLF4 comprises the amino acid sequence of SEQ ID NO: 45.

21. The method of claim 1 , wherein the expression vector does not encode other transcription factors besides OCT4, SOX2, and KLF4.

22. The method of claim 1 , wherein after the contacting step, the neuronal cells do not express at least one stem cell marker.

23. The method of claim 22 , wherein the at least one stem cell marker is Esrrb, Nanog, Lin28, TRA-1-60/TRA-1-81/TRA-2-54, SSEA1, SSEA4, or any combination thereof.

Assignees

• Harvard College

Inventors

• Sinclair David A
• Lu Yuancheng

Classifications

• C12N2750/14143

  viral genome or elements thereof as genetic vector · CPC title

• C12N15/86

  Viral vectors · CPC title

• A61K31/65

  Tetracyclines · CPC title

• A61K2300/00

  Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00 · CPC title

• C07K14/47

  from mammals · CPC title